What does HPLC purity mean for a synthetic peptide like hexarelin?
In peptide analytical chemistry, HPLC purity is a relative area-percent value: the peak area attributed to the target peptide divided by the total integrated peak area across the chromatogram, expressed as a percentage. For hexarelin this is typically determined by reversed-phase HPLC, where the peptide partitions between a hydrophobic stationary phase (commonly C18) and a gradient mobile phase of water and acetonitrile modified with an ion-pairing acid. Hexarelin's two tryptophan-related residues and free lysine side chain give it distinctive hydrophobicity and UV absorbance, allowing detection at 214 nm (peptide bond) and 280 nm (aromatic residues). It is important to understand that HPLC purity is method-dependent: the same batch analysed under different gradients, column chemistries or ion-pairing reagents can return different area-percent figures because co-eluting impurities may separate or merge. A robust characterisation therefore documents the column, particle size, mobile-phase composition, gradient slope, flow rate, detection wavelength and injection load, so the reported purity is reproducible and comparable across lots. Synthetic process-related impurities in a peptide like hexarelin include deletion sequences, truncated chains, incomplete deprotection products and diastereomers arising from partial racemisation during solid-phase synthesis. Because these species are structurally similar to the parent, they may elute close to the main peak, which is why gradient optimisation and adequate resolution are central to a meaningful purity number. A single area-percent figure divorced from its method is not interpretable; the value only has meaning within a fully specified, validated chromatographic method that a reviewing laboratory can scrutinise (DOI:10.1080/10826079408013498).
How is reversed-phase HPLC method development optimised for hexarelin?
Reversed-phase method development for a hexapeptide balances resolution, run time and peak shape. For hexarelin, a typical starting point is a C18 column (for example 150 mm x 4.6 mm, 3–5 µm particles) with a linear acetonitrile gradient against an aqueous phase containing 0.1% trifluoroacetic acid (TFA) as the ion-pairing modifier. TFA sharpens peaks by suppressing residual silanol interactions with the basic lysine and histidine side chains. Method development iterates on gradient slope: a shallow gradient improves separation of closely eluting deletion or diastereomeric impurities at the cost of longer run times, while a steeper gradient is faster but risks co-elution. Column temperature (often 25–40 °C) is controlled to stabilise retention time and improve reproducibility. Injection load is optimised so the main peak is neither overloaded (causing fronting and masked impurities) nor so dilute that low-level related substances fall below the limit of quantitation. System suitability parameters — theoretical plate count, tailing factor, resolution between the main peak and its nearest neighbour, and replicate-injection retention-time and area precision — are established and recorded before sample analysis. An orthogonal confirmation using a differing selectivity, such as a different ion-pairing reagent or column chemistry, strengthens confidence that no impurity is hidden under the main peak. Biomimetic and gradient RP-HPLC approaches have been applied to characterise peptide drug candidates and their physicochemical behaviour, illustrating how chromatographic conditions are tuned to the analyte's properties (DOI:10.5599/admet.547). Documenting each of these method parameters in the analytical record is what allows a subsequent laboratory to reproduce the purity determination and defend it during an audit or supplier comparison.
Why is peak purity assessment important, and how is it performed?
A high area-percent value is only trustworthy if the main peak is spectrally homogeneous — that is, if it represents a single component rather than two or more co-eluting species. Peak purity assessment addresses this directly. Using a photodiode-array (PDA) detector, spectra are acquired across the leading edge, apex and trailing edge of the hexarelin peak. If the peak is pure, these spectra are superimposable and the software-computed purity angle stays below the purity threshold; a co-eluting impurity with a differing UV spectrum produces spectral non-homogeneity that the algorithm flags. Because hexarelin's aromatic residues give a characteristic UV signature, PDA-based purity checks are informative, though they cannot detect impurities that share an identical spectrum. For that reason, spectral peak-purity testing is complemented by mass-spectrometric detection, which resolves co-eluting species by mass even when their UV spectra overlap. Combining RP-HPLC with electrospray mass detection allows both a purity estimate and the assignment of impurity masses in a single high-throughput workflow, an approach validated for synthetic peptide characterisation (DOI:10.1111/j.1399-3011.1996.tb00809.x). A defensible characterisation record for hexarelin therefore reports the peak-purity method (detector type, wavelength range, purity threshold and angle) alongside the area-percent value. When a COA states a purity figure but omits how peak homogeneity was verified, the reviewing laboratory cannot exclude hidden co-elution — a key reason to read the methodology section, not just the headline number. Peak-purity documentation is one of the most frequently overlooked but most diagnostic elements of a peptide quality record.
How is hexarelin identity confirmed by mass spectrometry?
HPLC establishes purity and relative retention, but it does not by itself prove that the main peak is hexarelin. Identity is confirmed orthogonally, most commonly by electrospray ionisation mass spectrometry (ESI-MS), which measures the intact molecular mass. Hexarelin has a defined theoretical monoisotopic and average mass derived from its six-residue amidated sequence; an observed mass within a tight tolerance of the theoretical value supports identity. ESI typically produces singly and doubly protonated species for a peptide of this size, and deconvolution of the multiply charged envelope yields the neutral mass. Where finer confirmation is required, tandem mass spectrometry (MS/MS) fragments the peptide to generate b- and y-ion series that map the amino-acid sequence, allowing verification of the specific residue order and detection of sequence variants or deletion impurities. Coupling mass detection to the chromatographic separation (LC-MS) also permits mass assignment of individual impurity peaks, distinguishing, for example, an oxidation product (mass shift of +16 Da) from a deletion sequence (loss of a residue mass). The combined LC-ESI-MS strategy for simultaneous purity estimation and identity characterisation of synthetic peptides is well established (DOI:10.1111/j.1399-3011.1996.tb00809.x). A complete hexarelin characterisation record should therefore present both the HPLC purity chromatogram and the mass spectrum with the theoretical and observed masses stated, so that identity and purity are documented as distinct, mutually reinforcing measurements rather than inferred from a single assay.
What impurities and stereochemical concerns matter for hexarelin?
Hexarelin's sequence includes a D-configured, methylated tryptophan analogue and a D-phenylalanine, which are introduced deliberately during synthesis. Any partial racemisation or use of amino-acid building blocks with sub-optimal enantiomeric purity can generate diastereomeric impurities that are chemically almost identical to the target but differ in three-dimensional structure and chromatographic retention. Monitoring the enantiomeric and diastereomeric purity of protected amino-acid derivatives used in peptide synthesis is a recognised quality-control concern, since building-block impurities propagate into the final peptide (DOI:10.1080/10826079408013498). Beyond stereochemistry, process-related impurities include deletion sequences (a residue omitted during coupling), truncated peptides, incompletely deprotected species and residual scavenger adducts. Degradation-related species can also arise during handling and storage: oxidation of the tryptophan/aromatic residues, and hydrolysis or deamidation over time. A thorough related-substances analysis integrates and, where possible, mass-identifies these peaks rather than lumping them into an undifferentiated 'impurities' total. The counterion is a further consideration: peptides purified with TFA-containing mobile phases carry TFA as a counterion, and residual TFA content is a distinct analytical parameter from chromatographic purity. Documenting these categories — stereochemical, process-related and degradation impurities plus counterion content — gives a far more informative picture than a single purity percentage. For a research laboratory comparing hexarelin lots, an impurity profile that names and quantifies the principal related substances is a stronger quality indicator than a bare purity figure, because it reveals whether the same impurity is consistently present across batches, which speaks to synthetic-process control.
How should a hexarelin certificate of analysis be read and documented?
A hexarelin COA is a quality-control document, and reading it critically is a core laboratory skill. Look first for unambiguous identity: the stated sequence, molecular formula, theoretical mass and the observed mass from ESI-MS, ideally with the spectrum reproduced. Next, examine the HPLC purity section for the full method (column, mobile phase, gradient, wavelength) and the reported area-percent, and check whether peak purity was assessed by PDA or LC-MS. A credible COA also reports related substances, counterion content, water content by Karl Fischer and net peptide content, since chromatographic purity alone does not describe how much actual peptide is present in the vial after salt and moisture are accounted for. Batch traceability — lot number, manufacture date, retest or reference date and analyst sign-off — links the physical material to its data, which matters for reproducible research and for supplier accountability. Where a lot-release framework is applied, pre-defined acceptance criteria are compared against the measured results, and any out-of-specification result is documented with its disposition. The broader endocrine research literature on hexarelin underscores why precise identity matters: work characterising its receptor interactions and comparative pharmacology depends on knowing the material is the intended compound (DOI:10.1046/j.1365-2265.1997.3121128.x; DOI:10.1530/eje.0.1410313). Retaining the COA alongside your internal reconstitution and storage records builds a complete, auditable chain of documentation. Treating the COA as data to be interpreted — not a marketing badge — is what distinguishes rigorous laboratory practice from box-ticking, and it is central to reproducible peptide research.
Apply this checklist to documented stock
You now have a practical way to read purity figures, method notes, and lot traceability. When you source materials, hold suppliers to that same checklist — ClaraScience issues batch documentation with every order and dispatches from Australian warehouses with Express tracked shipping.
Start with a retail order to review documentation end-to-end, or register for wholesale if you restock multiple compounds.
Frequently asked questions
What HPLC purity is typically reported for research hexarelin?
Research-grade synthetic hexarelin is commonly characterised at high area-percent purity by RP-HPLC, but the figure is only meaningful with its method. A responsible characterisation states the column, gradient, ion-pairing modifier and detection wavelength, plus whether peak purity was confirmed spectrally or by LC-MS, so the value can be reproduced and compared between lots.
Why is mass spectrometry needed if HPLC already shows high purity?
HPLC purity is a relative area measurement and cannot confirm chemical identity or detect impurities that co-elute under an identical UV spectrum. Electrospray mass spectrometry supplies the intact molecular mass, and tandem MS can verify the sequence, making identity and purity independent, mutually reinforcing measurements rather than a single inferred number.
What are the main impurities to expect in synthetic hexarelin?
Typical process-related impurities include deletion and truncated sequences, incompletely deprotected species, diastereomers from partial racemisation, and oxidation products of aromatic residues. Because hexarelin contains D-configured residues, enantiomeric purity of the synthesis building blocks is an important upstream quality consideration reflected in the impurity profile.
What is peak purity assessment on a hexarelin chromatogram?
Peak purity assessment uses photodiode-array spectra taken across the peak to test whether it represents a single component. If leading, apex and trailing spectra match, the peak is spectrally homogeneous. It is complemented by LC-MS because co-eluting species with identical UV spectra can only be resolved by mass.
Does HPLC purity tell me how much peptide is in the vial?
No. Chromatographic purity is a relative measure of the target peak against total peaks. It does not account for counterion (such as TFA) or water content. Net peptide content, determined with Karl Fischer water analysis and salt correction, describes the actual quantity of peptide present in the vial.
References
- DOI:10.1007/bf03345625 — Hexarelin: A multi-receptor peptide — Journal of Endocrinological Investigation — 2008
- DOI:10.1111/j.1399-3011.1996.tb00809.x — High‐throughput purity estimation and characterisation of synthetic peptides by electrospray mass spectrometry — International Journal of Peptide and Protein Research — 1996
- DOI:10.1080/10826079408013498 — HPLC Determination of Enantiomeric Purity of Protected Amino Acid Derivatives Used in Peptide Synthesis — Journal of Liquid Chromatography — 1994
- DOI:10.5599/admet.547 — In vitro biomimetic HPLC and in vivo characterisation of GM6, an endogenous regulator peptide drug candidate for amyotrophic lateral sclerosis — ADMET and DMPK — 2018
- DOI:10.1046/j.1365-2265.1997.3121128.x — Interaction of the growth hormone releasing peptide hexarelin with somatostatin — Clinical Endocrinology — 1997
- DOI:10.1530/eje.0.1410313 — Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin — European Journal of Endocrinology — 1999
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
